Virtu Financial LLC Purchases New Position in Sonnet BioTherapeutics Holdings, Inc. (NASDAQ:SONN)

Virtu Financial LLC purchased a new position in shares of Sonnet BioTherapeutics Holdings, Inc. (NASDAQ:SONN) during the fourth quarter, according to the company in its most recent filing with the Securities & Exchange Commission. The institutional investor purchased 39,647 shares of the company’s stock, valued at approximately $58,000. Virtu Financial LLC owned approximately 1.30% of Sonnet BioTherapeutics at the end of the most recent quarter.

Sonnet BioTherapeutics Stock Up 2.3 %

SONN opened at $1.34 on Tuesday. The firm’s fifty day simple moving average is $1.52 and its two-hundred day simple moving average is $2.41. Sonnet BioTherapeutics Holdings, Inc. has a 52-week low of $1.22 and a 52-week high of $16.80.

Sonnet BioTherapeutics (NASDAQ:SONN) last posted its quarterly earnings data on Thursday, February 13th. The company reported ($1.56) earnings per share (EPS) for the quarter, topping the consensus estimate of ($11.12) by $9.56. The firm had revenue of $1,000 billion during the quarter.

Analysts Set New Price Targets

Separately, Chardan Capital reaffirmed a “buy” rating and set a $20.00 target price on shares of Sonnet BioTherapeutics in a research note on Friday.

Sonnet BioTherapeutics Profile

Sonnet BioTherapeutics Holdings, Inc, a biotechnology company, owns a platform for biologic medicines of single or bifunctional action. The company develops fully human albumin binding technology, which utilizes human single chain antibodies fragment that binds to and hitch-hikes on human serum albumin for transport to target tissues.